Maintenance therapy with midostaurin has been approved by EMA and reflects the standard of care in AML patients harboring either FLT3-ITD or FLT3-TKD mutations, undergoing conventional induction and consolidation chemotherapy without alloHSCT. The gene discussed is FLT3; the disease is acute myeloid leukemia.